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Background: Anastrozole (A) has been shown to prevent breast cancer in postmenopausal women at increased risk of developing the disease, but has been associated with substantial accelerated bone mineral density (BMD) loss during active treatment. Here, we investigate changes in BMD assessed by dual energy X-ray absorptiometry (DXA) 2 years after treatment cessation in women included in the IBIS-II breast cancer prevention trial.
Methods: IBIS II randomly assigned 3864 postmenopausal women to A 1mg/day or placebo (P) for 5 years. 1410 were included in a BMD sub-study and stratified into three strata according to their baseline T-score at spine or femoral neck (stratum I (N=760): T-score>-1.0 and observed; stratum II (N=500): -1.0<T-score>-2.5 and randomised to weekly risedronate or placebo; stratum III (N=150): -2.5<T-score>-4.0 or/and two fragility fractures and all on risedronate). The primary objective of this analysis was to investigate whether DXA BMD at the spine and hip changed 2 years after stopping A or P. All results are presented as mean % BMD changes (95% CI) between 5 and 7 years of follow-up.
Results: 5 and 7-year BMD data were available for a total of 529 women who did not receive risedronate. In stratum I, cessation of A (N=205) led to an increase in BMD at the spine that was larger than in those on P (N=206) (A=1.29% (95% CI 0.78 to 1.79) vs. P=0.2% (-0.23 to 0.62), p=0.001). At the hip, BMD remained unchanged between 5 and 7 years after cessation of A but continued to a decrease in those who had been on P (A=-0.07% (-0.51 to 0.37) vs. P=-1.31% (-1.67 to 0.94), p<0.0001). Similar results were observed for women with osteopenia (stratum II). Those previously on A (N=53) had a significantly larger BMD increase at the spine after treatment cessation compared to those stopping P (N=64) (A=2.81% (1.40 to 4.23) vs. P=0.57% (-0.36 to 1.50); p=0.007). Loss of BMD at the hip continued in women who had been on P but increased slightly following cessation of A (A=0.47% (-0.42 to 1.36) vs. P=-1.33% -2.12 to -0.54); p=0.003). 
Conclusions: These are the first results reporting BMD changes after stopping A in a breast cancer prevention setting. BMD at the lumbar spine improved significantly more in women who were originally randomised to A compared to those who received P. Our results show that the negative effects of A on BMD in the preventive setting are partially reversible. 


